Nanoparticle Formulation Solves Stability and Delivery Problems for Anticancer Peptide PEN-FFW | Research

The takeaway

A nanoparticle delivery system for the anticancer peptide PEN-FFW achieved 50% better encapsulation, improved stability, and greater liver accumulation in mice compared to free peptide.

50% increase in encapsulation efficiency
Systematic optimization of the nanoparticle formulation dramatically improved how much PEN-FFW peptide could be loaded, while also enhancing stability and liver targeting.

What the researchers found

Researchers developed a stable nanoformulation for the anticancer peptide PEN-FFW by encapsulating it in carboxymethyl cellulose-PLGA nanoparticles stabilized with polysorbate 80. Optimization using a Box-Behnken design achieved a 50% increase in encapsulation efficiency and enhanced storage stability. The formulation showed superior cellular uptake and cytotoxicity in liver cancer cells in vitro, and significantly greater hepatic retention compared to free peptide in mice.

Why it matters

A major challenge for peptide cancer drugs is that they break down quickly and don't reach tumors effectively. PEN-FFW shows promise against hepatocellular carcinoma (liver cancer), but its sensitivity to shear and poor stability have blocked development. This nanoformulation solves both problems, demonstrating that smart delivery systems can unlock the therapeutic potential of otherwise unstable peptide drugs.

The numbers in context

50% increase in encapsulation efficiency · enhanced storage stability · superior cellular uptake in vitro · greater hepatic retention in vivo · CMC-PLGA core · polysorbate 80 stabilizer · Box-Behnken 4-factor optimization

How the study worked

PEN-FFW was encapsulated in carboxymethyl cellulose-PLGA nanoparticles stabilized by polysorbate 80. Drug-excipient interactions were characterized by QCM-D, FTIR, and DLS. Molecular modeling predicted peptide binding within the polymer core. A four-factor, three-level Box-Behnken design optimized formulation parameters. In vitro testing assessed cellular uptake and cytotoxicity in HepG2 cells. In vivo studies in mice measured hepatic retention.

Who was studied

In vitro HepG2 liver cancer cells and in vivo mouse biodistribution study

What this study cannot tell us

Anti-tumor efficacy in tumor-bearing animal models was not reported — only hepatic retention was measured in vivo. Long-term stability under various storage conditions was not fully characterized. The scalability of the optimized formulation for commercial manufacturing was not assessed. Toxicity of the nanoformulation versus free peptide in healthy tissue was not compared.

How to read the evidence

This is a preclinical formulation development study with in vitro efficacy and in vivo biodistribution data. The formulation science is rigorous, but anti-tumor efficacy in tumor models and safety evaluation are still needed.

When this study was published

Published in 2025, this represents current advances in peptide nanoformulation technology for cancer therapy.

The bigger picture

Peptide drugs often fail in development not because they lack efficacy but because they can't be formulated into stable, effective drug products. This study exemplifies how nanotechnology can overcome peptide delivery challenges, a approach increasingly important as more therapeutic peptides enter the pipeline. The success of this formulation strategy could be applied to other fragile peptide candidates, particularly those targeting liver diseases.

Questions still open

Does the nanoformulated PEN-FFW show anti-tumor efficacy in liver cancer mouse models, not just hepatic retention?
Could this PLGA nanoparticle approach be adapted for other anticancer peptides with similar stability challenges?
What is the toxicity profile of the nanoformulation versus free PEN-FFW in healthy liver tissue?

Common questions

Why do peptide drugs need nanoparticle delivery systems?

Peptide drugs are typically fragile — they break down quickly in the bloodstream, don't cross cell membranes easily, and often don't accumulate in the right tissue. Nanoparticles protect peptides from degradation, can be engineered to release them slowly, and can be designed to accumulate in specific organs. For PEN-FFW, the nanoparticles protect the peptide and help it concentrate in the liver where the target cancer is.

What is PEN-FFW and how does it fight liver cancer?

PEN-FFW is an anticancer peptide with selective toxicity against hepatocellular carcinoma (liver cancer) cells and a favorable safety profile for normal cells. However, its development has been challenged by its sensitivity to physical stress and poor stability. The nanoformulation developed in this study overcomes these limitations, making it a more viable drug candidate.

Read the original research

Molecular insights into the formation of polymeric nanoassemblies of the anticancer peptide PEN-FFW.

Journal of controlled release : official journal of the Controlled Release Society, 388(Pt 2), 114364

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Tianqi; Lazareva, Polina A; Malinovskaya, Julia; Panczyk, Tomasz; Wen Hui, Joyce Ang; Dhakal, Namrata; Liu, Beijia; Qin, Qiuhua; Kovshova, Tatyana; Sur, Somok; Vadekhina, Veronika; Ivanova, Anna V; Valikhov, Marat; Reich, Gabriele; Chen, Wenqian; Gelperina, Svetlana; Abakumov, Maxim A; Wacker, Matthias G. (2025). Molecular insights into the formation of polymeric nanoassemblies of the anticancer peptide PEN-FFW.. Journal of controlled release : official journal of the Controlled Release Society, 388(Pt 2), 114364. https://doi.org/10.1016/j.jconrel.2025.114364